Comparative oncology reveals DNMT3B as a therapeutic vulnerability in soft-tissue sarcoma
A. M. Fuller, A. DeVine, I. Murazzi, N. J. Mason, K. Weber, T. S. K. Eisinger
The paper identifies DNMT3B overexpression in UPS and shows its role in poor prognosis, but existing inhibitors are ineffective due to toxicity and uptake issues.
bioRxiv · Dec 22, 2021 · PreprintCancer Biology